// App-Quantinova.ai

2622 : Phase I dose escalation study of 3-weekly BI 836845, a fully human, affinity optimized, insulin-like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid tumors.

Researchers

Presenter

  • Karim Rihawi

Principal Investigators

  • Michael Ong

  • Thomas Bogenrieder

  • Alan Anthoney

  • Johann Sebastian De Bono

  • Chris Twelves

  • Vasiliki Michalarea

  • Liz Bent

  • Susanne Buschke

Medical Centers

  • The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom

  • Drug Development Unit at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK, London, United KingdomThe Royal Marsden NHS Foundation Trust, Surrey, United KingdomUniversity of Leeds and St. Jamess University Hospital, Leeds, United Kingdom

  • Boehringer Ingelheim Ltd, Bracknell Berkshire, United Kingdom

  • Department of Medicine, University of Ottawa, Ottawa, ON, Canada

  • Boehringer Ingelheim RCV GmbH & Co. KG, Vienna, Austria

  • Boehringer Ingelheim, Biberach, Germany

  • Leeds Cancer Research UK Clinical Centre, Leeds, United Kingdom

Locations

  • Canada

  • United Kingdom

  • Germany

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Solid malignancies

  • Diabetes

Biomarkers

  • Insulin-like growth factor

Drug/Treatment

  • BI-836845

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01317420

Sponsors

  • Boehringer Ingelheim

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved